Pilot Study of the Efficacy and Safety of Q8003 in Patients Who Have Undergone Total Knee Arthroplasty or Total Hip Arthroplasty
Information source: QRxPharma Inc.
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Postoperative Pain
Intervention: Q8003 (morphine sulfate and oxycodone hydrochloride) (Drug); Low dose Q8003 (morphine sulfate and oxycodone hydrochloride) (Drug); Percocet (oxycodone and acetaminophen) (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: QRxPharma Inc. Official(s) and/or principal investigator(s): Patricia T. Richards, MD, Ph.D., Study Director, Affiliation: QRxPharma Inc.
Summary
This is a Phase 2 3-arm, open label pilot study of the safety and efficacy of Q8003 in
patients who have undergone primary unilateral total knee arthroplasty or total hip
arthroplasty.
Clinical Details
Official title: An Open-Label Pilot Study of the Analgesic Efficacy and Safety Of Q8003 and of the Conversion From IV Morphine PCA Analgesia to Q8003 or to Percocet® in Patients Who Have Undergone Primary Unilateral Total Knee Arthroplasty or Total Hip Arthroplasty
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Difference in pain intensity scores from baseline
Secondary outcome: Safety: adverse events
Detailed description:
This Phase 2 study is a 3 arm, open-label pilot study to evaluate:
- the analgesic efficacy of a flexible ascending regimen of Q8003 compared to a low dose
regimen of Q8003 (3 mg/2 mg and potentially up to 6 mg/ 4mg) and to 1-2 Percocet® 5
mg/325 mg tablets. Study drug will be administered every 4-6 hours over a 48-hour
Treatment Period to inpatients with moderate to severe postoperative pain who have
undergone primary unilateral total knee arthroplasty or total hip arthroplasty.
- for the flexible ascending regimen of Q8003 treatment group, to evaluate the adequacy
of the algorithm for conversion of IV PCA morphine to oral morphine equivalent doses of
Q8003.
- the safety of the flexible ascending regimen of Q8003 administered over a 48-hour
Treatment Period.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Male of female, at least 18 years of age at time of enrollment.
- If female, be at least one year post-menopausal, surgically sterile or practicing
effective contraception, be non-lactating, and if of child-bearing potential, have a
negative urine pregnancy test result.
- Have a body mass index (BMI) of 38 kg/m2 or less.
- Have undergone a primary unilateral total knee arthroplasty or total hip arthroplasty
performed under standardized general, spinal or epidural anesthesia.
- Have developed moderate to severe pain (a score of 2 or more on the 4 point Likert
scale or at least 4 on the 11 point NPRS scale within 6 hours of discontinuing PCA on
the morning after surgery).
Exclusion Criteria:
- In the opinion of the Investigator, has a history of pulmonary, cardiovascular
(including uncontrolled hypertension), neurologic, endocrine, hepatic,
gastrointestinal, or kidney disease or therapy that, in the opinion of the
Investigator, would jeopardize the patient's well being by participation in this
study or is mentally or emotionally unsuitable to participate, or unable/unwilling to
comply with the study assessments.
- Used opiates continuously (including tramadol) for more than ten days in the past
year.
- Hypersensitivity or poor tolerance to ibuprofen or short term opioids.
- Currently receiving any medications that are not at a stable dose (the same dose for
> 2 months prior to date of surgery).
- Was dosed with another investigational drug within 30 days prior to the Screening
Visit or has previously received treatment with Q8003.
- Current therapy with central nervous system depressant medications that might
increase the risks of treatment with opioids (other than those used with surgical
anesthesia).
- Current evidence of alcohol abuse (regularly drinks more than 4 units of alcohol per
day; 1 unit = ½ pint of beer, 1 glass of wine, or 1 ounce of spirit).
- History of abusing licit or illicit drug substances within five (5) years of study
entry.
- Has taken drugs known to interact with morphine or oxycodone metabolism, including,
but not limited to, phenothiazines, monoamine oxidase inhibitors (MAOI),
amphetamines, and muscle relaxants within the 4 weeks prior to the date of surgery.
Locations and Contacts
West Alabama Research, Inc., Birmingham, Alabama 35209, United States
Arizona Research Center, Phoenix, Arizona 85023, United States
William Beaumont Hospital, Royal Oak, Michigan 48073, United States
Research Concepts, Ltd., Houston, Texas 77024, United States
Additional Information
Starting date: February 2009
Last updated: May 15, 2012
|